The presentations detail the advantages and potential of the circVec 3.0 generation to improve on current mRNA-based technology for a range of therapeutic applications. In vivo expression data has shown an estimated circRNA half-life of over 600 hours vs. under 10 hours for linear mRNA, which translates to over 70 times prolonged RNA durability and 15 times enhanced protein expression.

Novel systemic LNP-delivery data demonstrates robust and durable circVec expression in spleen, far outperforming equivalent mRNA-vectors. This important finding has the potential to open up attractive therapeutic opportunities for the circVec technology in several areas, such as cell therapy. Further experimental work is currently ongoing to validate and characterize these observations.

"The recent results showing efficient and specific circVec delivery to spleen are very promising and hints at novel opportunities for our circular RNA platform in cell and immune therapies," said  Dr. Victor Levitsky, CSO of Circio. "A broad set of experiments to further investigate this observation, as well as in vivo testing of the novel circVec 3.0 generation, will read out over the next 6-12 weeks. The performance of circVec 3.0-AAV constructs is of particular interest, which we believe has the potential to transform current gold-standard AAV gene therapy and generate substantial partnering interest."

See below for titles and presentation materials:

RNA Leaders Europe Congress  
Title: Deploying circular RNA expression to boost gene therapy - AAV and beyond
Time & place: 5 March 2025, Basel, SwitzerlandPresenter: Dr. Erik Digman Wiklund, CEO

Biologics World Nordics 2025
Title: CircVec - A Novel Payload Expression Platform Based on Circular RNA Biogenesis: Features and Opportunities
Time & place: 5 March 2025, Stockholm, Sweden
Presenter: Dr. Victor Levitsky, CSO